VRCA on Nasdaq

Verrica Pharmaceuticals Inc.

We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Earth Science Tech, Inc., Sunshine Biopharma Inc. or BIOHARVEST SCIENCES INC., or pick any stock.

  • TickerVRCA on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersWest Chester, United States2
  • Incorporated inDE3
  • Business address44 West Gay Street, Suite 400, West Chester, Pa3
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493002L68H6THU5GW502
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 53615312

See how the biggest companies compare on our leaderboards

We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Our commercial product, YCANTH (VP-102), was approved by the U.S. Food and Drug Administration, or FDA, in July 2023 for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are currently developing YCANTH (VP-102) for a potential follow-on indicati…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-34.2%Operating margin5
-50.3%Net margin5
370.2%Revenue growth, 20255
-72.3%Return on equity5
0.00×Debt to equity5
-$17.6MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Collaboration revenue brought in 54% of the revenue Verrica Pharmaceuticals Inc. broke down this way in fiscal 2025.

  1. Collaboration revenue$20.3M554%up 1946% from 2024
  2. Product$15.3M540%up 133% from 2024
  3. License And Collaboration Revenue, Commercial Supply And Development$2.3M56%up 130% from 2024
Products and services by year
Products and services20242025
Collaboration revenue$992.0K$20.3M
Product$6.6M$15.3M
License And Collaboration Revenue, Commercial Supply And Development$1.0M$2.3M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development20¢$8.9M
  • Selling, general and admin80¢$35.2M

Out of $35.6M in revenue.5 The company lost money this year.

Financial statements

Revenue6785$35.6M in 2025+196% since 2021
0$10.0M$20.0M$30.0M$40.0M2021: $12.0M$12.0M20212022: $9.0M$9.0M2022−25%2023: $5.1M$5.1M2023−43%2024: $7.6M$7.6M2024+48%2025: $35.6M$35.6M2025+370%
Operating income9106785-$12.2M in 2025−59% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$30.1M-$30.1M20192020: -$40.2M-$40.2M2020+34%2021: -$30.9M-$30.9M2021−23%2022: -$21.3M-$21.3M2022−31%2023: -$65.8M-$65.8M2023+209%2024: -$65.9M-$65.9M2024+0%2025: -$12.2M-$12.2M2025−82%
Net income9106785-$17.9M in 2025−37% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$28.2M-$28.2M20192020: -$42.7M-$42.7M2020+51%2021: -$35.1M-$35.1M2021−18%2022: -$24.5M-$24.5M2022−30%2023: -$67.0M-$67.0M2023+174%2024: -$76.6M-$76.6M2024+14%2025: -$17.9M-$17.9M2025−77%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Total revenue$35.6M$7.6M
Cost of product revenue$2.2M$1.9M
Cost of license and collaboration revenue$1.2M$887.0K
Selling, general and administrative$35.2M$58.8M
Research and development$8.9M$11.8M
Loss on disposal of equipment$246.0K$83.0K
Total operating expenses$47.8M$73.5M
Loss from operations-$12.2M-$65.9M
Interest income$929.0K$1.4M
Interest expense-$7.7M-$9.4M
Change in fair value of derivative liability$2.6M-$2.6M
Loss on extinguishment of debt-$1.5M$0
Other expense-$3.0K-$17.0K
Total other expense, net-$5.7M-$10.7M
Net loss-$17.9M-$76.6M
Net loss per share, basic (in shares)-$1.68-$14.78
Net loss per share, diluted (in shares)-$1.68-$14.78
Weighted-average common shares outstanding, basic (in dollars per share)10.7M shares5.2M shares
Weighted-average common shares outstanding, diluted (in dollars per share)10.7M shares5.2M shares

Compare Verrica Pharmaceuticals Inc. with another company

Leadership

Who has led Verrica Pharmaceuticals Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jayson Rieger2024–now

President

  1. Jayson Rieger2024–now

Chief financial officer

  1. Chris Degnan2018–2019
  2. A. Brian Davis2019–2021
  3. Terry Kohler2021–2025
  4. John J. Kirby2024–now

Chief operating officer

  1. Linda Palczuk2018–2019
  2. David Zawitz2024–now
20202025
Board members and other officers (16)

Timeline

  1. Nov 6, 2024New chief executive Jayson Rieger becomes CEO13
  2. Jul 3, 2013Founded Verrica Pharmaceuticals Inc. is founded2

Filings

282 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 62 major events, 111 insider forms, 24 large holders, 1 private raises, 64 other. The latest 20:

  1. Aug 18, 20264 EDGAR
  2. Aug 18, 20264 EDGAR
  3. Aug 18, 20264 EDGAR
  4. Aug 18, 20264 EDGAR
  5. Aug 6, 202610-Q EDGAR
  6. Aug 6, 20268-K EDGAR
  7. Jun 9, 20264 EDGAR
  8. Jun 9, 20264 EDGAR
  9. Jun 9, 20264 EDGAR
  10. Jun 9, 20264 EDGAR
  11. Jun 9, 20264 EDGAR
  12. Jun 9, 20264 EDGAR
  13. Jun 9, 20264 EDGAR
  14. Jun 9, 20268-K EDGAR
  15. May 12, 202610-Q EDGAR
  16. May 12, 2026S-8 EDGAR
  17. May 12, 20268-K EDGAR
  18. Apr 20, 2026ARS EDGAR
  19. Apr 20, 2026DEFA14A EDGAR
  20. Apr 20, 2026DEF 14A EDGAR

The 282 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

67 open-market trades by officers, directors and large owners since October 2021: 34 buys and 33 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 18, 2026Rosenberg Noah L.CMOBuy2,030$4.92$10.0KForm 4
Aug 18, 2026Kirby John J.Interim CFOBuy5,000$4.93$24.6KForm 4
Aug 17, 2026Zawitz DavidChief Operating OfficerBuy6,000$4.98$29.9KForm 4
Aug 17, 2026Rieger JaysonCEO and PresidentBuy5,000$4.91$24.6KForm 4
Aug 17, 2026Rosenberg Noah L.CMOBuy4,200$4.91$20.6KForm 4
Aug 14, 2026Rieger JaysonCEO and PresidentBuy20,000$5.06$101.2KForm 4
Nov 25, 2025Zawitz DavidChief Operating OfficerBuy10,000$4.24$42.4KForm 4
Nov 25, 2025Rieger JaysonCEO and PresidentBuy94,311$4.24$399.9KForm 4
Nov 25, 2025Rosenberg Noah L.CMOBuy2,357$4.24$10.0KForm 4
Nov 25, 2025Kirby John J.Interim CFOBuy3,536$4.24$15.0KForm 4
Nov 25, 2025Manning Paul BDirectorBuy4,126,142$4.24$17.5MForm 4
Mar 17, 2025Hayes Christopher G.CHIEF LEGAL OFFICERSale4,315$0.65$2.8KForm 4
Nov 22, 2024Rieger JaysonCEO and PresidentBuy280,898Form 4
Nov 22, 2024Stalfort John A IIIDirectorBuy1,123,595Form 4
Nov 22, 2024Manning Paul BDirectorBuy22,921,348Form 4
Aug 27, 2024Hayes Christopher G.CHIEF LEGAL OFFICERSale9,530$2.46$23.4KForm 4
Aug 27, 2024Goldenberg GaryChief Medical OfficerSale3,601$2.46$8.9KForm 4
Aug 27, 2024Bonaccorso JoeCHIEF COMMERCIAL OFFICERSale8,993$2.46$22.1KForm 4
Aug 27, 2024Kohler TerryCHIEF FINANCIAL OFFICERSale7,899$2.46$19.4KForm 4
Aug 27, 2024White TedPRESIDENT AND CEOSale9,021$2.46$22.2KForm 4

All 67 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 25, 2025Raised $50 million in a private offering of equity Form D: 21 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 43. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Caligan Partners LP923,910$5.7M0.3%No change
Cannell Capital LLC783,923$4.8M3.3%+98,800
Affinity Asset Advisors, LLC707,338$4.3M0.2%No change
Velan Capital Investment Management LP471,559$2.9M1.8%No change
Armistice Capital, LLC426,304$2.6M0.1%−91,877
Boothbay Fund Management, LLC280,734$1.7M0.0%No change
Vanguard Capital Management LLC279,310$1.7M0.0%+90,552
Mariner, LLC207,230$1.3M0.0%+182,686
Geode Capital Management, LLC138,160$845.7K0.0%−757
BlackRock, Inc.74,344$455.0K0.0%+35,791
Vanguard Fiduciary Trust Co70,173$429.5K0.0%+5,072
Two Sigma Investments, LP40,825$249.8K0.0%−9,837
State Street Corp28,916$177.0K0.0%No change
Northern Trust Corp26,996$165.2K0.0%−4,584
DAFNA Capital Management LLC23,750$145.3K0.0%−129,962
Jane Street Group, LLC23,654$144.8K0.0%−25,557
Verdad Advisers, LP23,069$141.2K0.1%+10,971
Renaissance Technologies LLC21,769$133.2K0.0%−10,591
Legacy Trust16,584$101.5K0.0%−650
Fifth Third Bancorp14,000$85.7K0.0%New
Dimensional Fund Advisors LP13,888$85.0K0.0%New
XTX Topco Ltd13,723$84.0K0.0%New
Two Sigma Securities, LLC13,045$79.8K0.0%New
Beck Mack & Oliver LLC12,000$73.4K0.0%No change
UBS Group AG6,071$37.2K0.0%+1,801

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42